


AMENDMENTS TO THE CLAIMS

1-5. (Cancelled)

6. (Currently Amended) A composition for oral administration, ~~wherein a base comprising an enteric film-coated granule containing,~~

~~_____ wherein the granule comprises~~ an alkylendioxybenzene derivative represented by the general formula (I):



~~_____ {wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3},~~
~~or an acid addition salt thereof,~~

~~_____ which is dispersed in a matrix containing comprising one or more waxes, and an excipient is coated with an~~

~~_____ wherein the enteric film coating comprises a copolymer selected from the group consisting of methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, and combinations thereof.~~


7. (Currently Amended) The composition for oral administration according to claim 6, ~~wherein an amount of waxes is 5 to 70% the granule comprises 5 to 70% by weight relative to the base granule of the one or more waxes.~~

8. (Cancelled)

9. (Currently Amended) A capsule, ~~which is filled with containing an alkylendioxybenzene derivative or an acid addition salt thereof, comprising the composition for oral administration~~


according to claim ~~1~~ filled therein~~6~~.

10. **(Currently Amended)** A process for preparing a composition for oral administration, comprising kneading an alkylendioxybenzene derivative represented by the general formula (I):



(wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3),
 or an acid addition salt thereof,
which is dispersed in a matrix comprising one or more waxes, and an excipient to obtain a granule, and
coating the granule with an enteric film comprising a copolymer selected from the group consisting of methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, and combinations thereof.

11. **(Currently Amended)** ~~A~~ The composition
 for oral administration, ~~wherein a pharmaceutically active substance is an alkylendioxybenzene derivative represented by general formula (I):~~



~~(wherein m represents an integer of 2 to 5, and n represents an integer of 1 to 3)~~
~~or an acid addition salt thereof, and a time for releasing according to claim 6, which releases at least 80% of a~~ its initial content of the pharmaceutically active substance is the

alkylenedioxybenzene derivative or the acid addition salt thereof within about 2 to about 24 hours when tested at 100 rotations per minute using 900 ml of a hydrochloric acid/trisodium phosphate buffer (pH 6.8) as a test solution according to a basket method (USP dissolution test first method).

12. **(Currently amended)** The composition for oral administration according to claim ~~4~~6, wherein the alkylenedioxybenzene derivative or the acid addition salt thereof is 5-[3-[[~~(2S)~~-1,4-benzodioxan-2-ylmethyl]amino]propoxy]-1,3-benzodioxole hydrochloride.

13-20. **(Cancelled)**

21. **(New)** The composition for oral administration according to claim 6, wherein the one or more waxes are selected from the group consisting of shellac, gelatin, hydrogenated beef tallow, hydrogenated castor oil, hydrogenated cottonseed oil, hydrogenated soybean oil, stearic acid, palmitic acid, aluminium monostearate, glyceryl mono- or dipalmitate, glyceryl mono-, di- or tristearate, cetyl alcohol, stearyl alcohol, myristyl alcohol, 12-hydroxystearyl alcohol, beeswax, Japan wax, carnauba wax, paraffin wax, whale wax, and synthetic wax.

22. **(New)** The composition for oral administration according to claim 6, wherein the granule comprises 20 to 40% by weight of the enteric film coating.

23. **(New)** The composition for oral administration according to claim 6, wherein the granule comprises 20 to 50% by weight of the one or more waxes.